Cargando…

The K(+) Channel Opener 1-EBIO Potentiates Residual Function of Mutant CFTR in Rectal Biopsies from Cystic Fibrosis Patients

BACKGROUND: The identification of strategies to improve mutant CFTR function remains a key priority in the development of new treatments for cystic fibrosis (CF). Previous studies demonstrated that the K(+) channel opener 1-ethyl-2-benzimidazolone (1-EBIO) potentiates CFTR-mediated Cl(−) secretion i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roth, Eva K., Hirtz, Stephanie, Duerr, Julia, Wenning, Daniel, Eichler, Irmgard, Seydewitz, Hans H., Amaral, Margarida D., Mall, Marcus A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164200/ https://www.ncbi.nlm.nih.gov/pubmed/21909392 http://dx.doi.org/10.1371/journal.pone.0024445

Ejemplares similares

Measurements of CFTR-Mediated Cl(−) Secretion in Human Rectal Biopsies Constitute a Robust Biomarker for Cystic Fibrosis Diagnosis and Prognosis
por: Sousa, Marisa, et al.
Publicado: (2012)

ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies
por: Mall, Marcus A.
Publicado: (2020)

CFTR Regulates Early Pathogenesis of Chronic Obstructive Lung Disease in βENaC-Overexpressing Mice
por: Johannesson, Bjarki, et al.
Publicado: (2012)

Personalized CFTR Modulator Therapy for G85E and N1303K Homozygous Patients with Cystic Fibrosis
por: Graeber, Simon Y., et al.
Publicado: (2023)

Mutant CFTR Drives TWIST1 mediated epithelial–mesenchymal transition
por: Quaresma, Margarida C., et al.
Publicado: (2020)

A European regulatory perspective on cystic fibrosis: current treatments, trends in drug development and translational challenges for CFTR modulators
por: Ponzano, Stefano, et al.
Publicado: (2018)

Correcting the Cystic Fibrosis Disease Mutant, A455E CFTR
por: Cebotaru, Liudmila, et al.
Publicado: (2014)

Assessment of Distinct Electrophysiological Parameters in Rectal Biopsies for the Choice of the Best Diagnosis/Prognosis Biomarkers for Cystic Fibrosis
por: Silva, Iris A. L., et al.
Publicado: (2020)

Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis
por: Olivier, Margarete, et al.
Publicado: (2023)

CFTR, Cell Junctions and the Cytoskeleton
por: Pankonien, Ines, et al.
Publicado: (2022)

Rectal forceps biopsy procedure in cystic fibrosis: technical aspects and patients perspective for clinical trials feasibility
por: Servidoni, Maria F, et al.
Publicado: (2013)

Folding–function relationship of the most common cystic fibrosis–causing CFTR conductance mutants
por: van Willigen, Marcel, et al.
Publicado: (2019)

A small molecule CFTR potentiator restores ATP‐dependent channel gating to the cystic fibrosis mutant G551D‐CFTR
por: Liu, Jia, et al.
Publicado: (2022)

Integrity and Stability of PTC Bearing CFTR mRNA and Relevance to Future Modulator Therapies in Cystic Fibrosis
por: Clarke, Luka A., et al.
Publicado: (2021)

CFTR mutations altering CFTR fragmentation
por: Tosoni, Kendra, et al.
Publicado: (2012)

Rescue of Mutant CFTR Trafficking Defect by the Investigational Compound MCG1516A
por: Lopes-Pacheco, Miquéias, et al.
Publicado: (2022)

EBioMedicine: Translating Science to Improve Health
por: EBioMedicine
Publicado: (2018)

Happy 5th birthday, EBioMedicine!
Publicado: (2019)

Cystic Fibrosis, CFTR, and Colorectal Cancer
por: Scott, Patricia, et al.
Publicado: (2020)

Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis
por: Sermet-Gaudelus, Isabelle, et al.
Publicado: (2018)

What Role Does CFTR Play in Development, Differentiation, Regeneration and Cancer?
por: Amaral, Margarida D., et al.
Publicado: (2020)

Pharmacological Correctors of Mutant CFTR Mistrafficking
por: Pedemonte, Nicoletta, et al.
Publicado: (2012)

Multicenter Intestinal Current Measurements in Rectal Biopsies from CF and Non-CF Subjects to Monitor CFTR Function
por: Clancy, John P., et al.
Publicado: (2013)

EBioMedicine: Bridging Two Cultures to Improve Health
Publicado: (2014)

CFTR and Ca(2+) Signaling in Cystic Fibrosis
por: Antigny, Fabrice, et al.
Publicado: (2011)

Strategies to circumvent the CFTR defect in cystic fibrosis
por: Becq, Frédéric, et al.
Publicado: (2013)

Not All Is CFTR – Neutrophils and Cholesterol in Cystic Fibrosis
por: Castellani, Stefano, et al.
Publicado: (2017)

Cystic Fibrosis and Oxidative Stress: The Role of CFTR
por: Moliteo, Evelina, et al.
Publicado: (2022)

CFTR modulators: transformative therapies for cystic fibrosis
por: Dwight, Mary, et al.
Publicado: (2021)

Ivacaftor modifies cystic fibrosis neutrophil phenotype in subjects with R117H residual function CFTR mutations
por: Hardisty, Gareth R., et al.
Publicado: (2021)

Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors
por: Amico, Giulia, et al.
Publicado: (2019)

Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation
por: Stefano, Daniela De, et al.
Publicado: (2014)

CFTR Modulator Therapy with Lumacaftor/Ivacaftor Alters Plasma Concentrations of Lipid-Soluble Vitamins A and E in Patients with Cystic Fibrosis
por: Sommerburg, Olaf, et al.
Publicado: (2021)

Personalized Medicine Based on Nasal Epithelial Cells: Comparative Studies with Rectal Biopsies and Intestinal Organoids
por: Silva, Iris A. L., et al.
Publicado: (2021)

Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles
por: Taylor-Cousar, Jennifer L., et al.
Publicado: (2019)

Effects of lumacaftor—ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in F508del homozygous patients with cystic fibrosis aged 2–11 years
por: Berges, Julian, et al.
Publicado: (2023)

Nanomolar-potency ‘co-potentiator’ therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutants
por: Phuan, Puay-Wah, et al.
Publicado: (2019)

Inflammation and CFTR: might neutrophils be the key in cystic fibrosis?
por: Witko-Sarsat, V, et al.
Publicado: (1999)

Fixing cystic fibrosis by correcting CFTR domain assembly
por: Okiyoneda, Tsukasa, et al.
Publicado: (2012)

Targeted therapies to improve CFTR function in cystic fibrosis
por: Brodlie, Malcolm, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vo3844fdtsmbp0q4f7gdfu6ss7